Two well-known pharmaceutical companies "marriage" to expand the integration of raw materials pharmaceutical business layout

"Pharmaceutical Network Industry Dynamics" recently reported that Zhejiang Jiuzhou Pharmaceutical Co., Ltd. ("Kyuszhou Pharmaceuticals") and Shanghai Pharmaceutical Group Co., Ltd. ("Shanghai Pharmaceuticals") are planning to set up a joint venture in Taizhou.
's proposed joint venture, with the aim of developing high-end generics and improved new drugs, will be jointly funded in monetary terms by Shanghai Pharmaceuticals, Jiuzhou Pharmaceuticals and equity incentive platforms, with a registered capital of RMB 500 million.
, the joint venture is tentatively named Zhejiang Shanghai Pharmaceutical Jiuzhou Biopharmaceutical Co., Ltd., registered in the Taizhou Research Institute of Zhejiang University.
Jiuzhou Pharmaceuticals is a high-tech enterprise that combines research and development, production and sale of pharmaceutical API and intermediates, and its main product categories include related API and Intermediate Contract Custom Research and Development and Production Business (CDMO), Specialty API and Intermediate Business (API).
On the evening of September 7, Kyuschu Pharmaceuticals also announced that it plans to raise no more than 1 billion yuan, which will be used to expand production capacity, strengthen the service capacity of the entire industrial chain, especially CDMO, and enhance the process research and development capabilities of drugs to provide adequate protection for the business development of listed companies.
and Shanghai Pharma has advantages in preparation production, network layout and so on.
In the production of preparations, in the first half of the year, Shanghai Pharma added 7 varieties (7 product rules) generic drug evaluation, the cumulative number of evaluation reached 13 varieties (16 product regulations), and more than 60 product regulations into the review and approval process, the number of the forefront of the industry.
in the third batch of drugs, the company participated in the bidding of 8 varieties of a total of 6 varieties (7 varieties) won the bid.
also made a lot of big varieties in BD.
addition, Shanghai Pharmaceuticals' import business has been in the national position for many years, with a number of new drugs imported, including Keytruda, Opdivo and so on.
first half of this year, Shanghai Pharma obtained the national total authority to import 8 new drugs and 2 imported innovative vaccines.
in terms of network layout, since this year, the company's Shanghai Pharmaceutical Cloud Health has docked 31 Internet hospitals, and with many of them reached a distribution entrustment relationship, while B round of financing is also in an orderly manner.
its participating subsidiary Magnesium Health, as the first full-cycle medical innovation payment platform in China, has been valued at nearly 1 billion yuan since its inception three years, and has also launched round B financing.
the two sides will now connect their own advantages, the realization of the state-owned system and private institutional mechanism of a new combination.
For Kyushe Pharmaceuticals, after the formation of the new company, the two sides will make full use of their respective research and development, registration, production and sales advantages in the API and preparation business areas, through the formation of a market-oriented professional team, the selection of Kyushe Pharmaceuticals has a competitive advantage of raw materials drug species, with the joint venture as the main body and as the drug market license holder, drug preparation development and registration declaration, access to drug registration approval and listing.
For Shanghai Pharma, this cooperation will help to further release the company's high-end preparation capacity and rich product categories, while ensuring the company's production and development of API products through in-depth strategic cooperation with high-quality suppliers of upstream API, to achieve the company's pharmaceutical industry sector business sustained and stable growth.
for varieties with market prospects or unseeded clinical needs, the two sides will carry out integrated development of API preparations.
it is understood that Kyuszhou Pharmaceuticals and Shanghai Pharmaceuticals have more than 10 years of commercial cooperation history, the two sides decided to set up a joint venture, which means that the cooperative relationship further.